Worldwide, prostate cancer is the most commonly diagnosed male cancer and the fourth leading cause of cancer death in men. Risk stratification is according to cancer stage, Gleason score, and PSA level . Definitive treatment of localized disease ( low and favorable intermediate risk) includes watchful waiting , active surveillance , radiation therapy , radical prostatectomy and cryotherapy .Primary treatment of unfavorable intermediate risk , high risk localized disease and locally advanced prostate cancer , includes both radical prostatectomy (RP) and EBRT + long-term androgen deprivation therapy (ADT) .Treatment options of metastatic prostate cancer include pain medications, bisphosphonates, hormonal treatment, chemotherapy, radiotherapy, immunotherapy, focused radiation, and other targeted therapies .
Study Type
OBSERVATIONAL
Enrollment
100
outcome of hormonal treatment as androgen deprivation therapy on prostate cancer patient on survival and relapse
outcome of radiotherapy as external beam radiotherapy on prostate cancer patient on survival and relapse
Sohag University Hospital
Sohag, Egypt
overall survival
Overall survival defined as the time from the date of diagnosis to the last date seen .
Time frame: 6 months
progression free survival
Progression-free survival defined as the length of time during and after the treatment of cancer that a patient lives with the disease but it does not get worse.
Time frame: 6 months
disease free survival
Disease free survival defined as the time from the end of treatment to the date of first relapse .
Time frame: 6 months
Ali M Ali, assisstant professor
CONTACT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.